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                                    Estrogen plays a fundamental role in the pathogenesis and devel-
opment of breast cancer, and the risk of this disease is associated 
with several factors related to the level and length of exposure to 
this hormone (  1  ,  2  ). In women diagnosed with breast cancer, after 
initial treatment with surgery, the concentration of circulating 
estrogen can be reduced by ovarian ablation using surgery, irradia-
tion, or luteinizing hormone  –  releasing hormone (LHRH) ago-
nists. These treatments, designed to prevent recurrence after 
surgery, have a clear beneficial effect in premenopausal women 
with breast cancer. In 2005, the Early Breast Cancer Trialists  ’   
Collaborative Group (EBCTCG) conducted a meta-analysis of 
several randomized trials investigating the effect of ovarian abla-
tion or suppression. They reported a 17% reduction in recurrence 
and a 13% reduction in breast cancer mortality among women 
younger than 50 years with estrogen receptor (ER)  –  positive or 
unknown disease (  3  ). The meta-analysis was based on an average 
follow-up of 8 years for trials of surgery or irradiation and 5 years 
for trials of LHRH agonists. 
  In 2007, a more detailed systematic review and analysis 
focused on adjuvant randomized trials that used LHRH agonists 
(  4  ) and was based largely on 9022 women with tumors positive for 
ER, progesterone receptor, or both. In these trials, women were 
randomly assigned to receive an LHRH agonist or not, with 
other comparisons based on chemotherapy or tamoxifen. The 
analysis revealed statistically signiﬁ  cant reductions in recurrence 
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     Background     Systematic reviews have found that luteinizing hormone  –  releasing hormone (LHRH) agonists are effective 
in treating premenopausal women with early breast cancer.   
     Methods     We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal 
Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamox-
ifen (20 or 40 mg daily), given for 2 years. Women were randomly assigned to receive each therapy alone, 
both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy). Hazard ratios 
and absolute risk differences were used to assess the effect of goserelin treatment on event-free survival   
(breast cancer recurrence, new tumor or death), overall survival, risk of recurrence of breast cancer, and 
risk of dying from breast cancer, in the presence or absence of tamoxifen.   
     Results     Fifteen years after the initiation of treatment, for every 100 women not given tamoxifen, there were 13.9 
(95% confidence interval [CI] = 17.5 to 19.4) fewer events among those who were treated with goserelin 
compared with those who were not treated with goserelin. However, among women who did take tamox-
ifen, there were 2.8 fewer events (95% CI =    7.7 fewer to 2.0 more) per 100 women treated with goserelin 
compared with those not treated with goserelin. The risk of dying from breast cancer was also reduced at 
15 years: For every 100 women given goserelin, the number of breast cancer deaths was lower by 2.6 
(95% CI = 6.6       fewer to 2.1 more) and 8.5 (95% CI     =     2.2 to 13.7) in those who did and did not take tamoxifen, 
respectively, although in the former group the difference was not statistically significant.   
     Conclusions     Two years of goserelin treatment was as effective as 2 years of tamoxifen treatment 15 years after starting 
therapy. In women who did not take tamoxifen, there was a large benefit of goserelin treatment on sur-
vival and recurrence, and in women who did take tamoxifen, there was a marginal potential benefit on 
these outcomes when goserelin was added.   
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and death after recurrence of 13% and 15%, respectively, with 
the addition of an LHRH agonist to women who received 
tamoxifen, chemotherapy, or both. 
  The Zoladex in Premenopausal Patients (ZIPP) study evaluated 
goserelin and tamoxifen separately and in combination in pre-
menopausal women with early breast cancer (  5  ). We have obtained 
long-term follow-up data on all the patients, probably longer than 
any other trial of an LHRH agonist, allowing us to examine differ-
ences in survival and risk of recurrence many years after the start 
of therapy. 
    Methods 
  The ZIPP trial was conducted jointly by 4 breast cancer study 
groups from Cancer Research UK (CRUK, formerly Cancer 
Research Campaign), Gruppo Interdisciplinare Valutazione 
Interventi in Oncologia (GIVIO) Italy, South East Sweden, and 
Stockholm. Details of its design and initial results have been pre-
sented elsewhere (  5  ). The aim was to determine whether the addi-
tion of goserelin (Zoladex) to local treatment, with or without 
tamoxifen, provided a benefit in survival or recurrence among pre- 
or perimenopausal women with operable, early breast cancer. The 
investigators in each location used the same protocol and worked 
together when setting up and conducting the trial. The sample size 
was based on all groups together. The local ethics committee for 
each center taking part in the trial approved the protocol, and all 
patients provided informed consent. 
    Trial Design and Subsequent Modifications 
  A total of 2710 premenopausal women were recruited from 
August 27, 1987, to March 22, 1999, and randomly assigned to 
receive goserelin alone (3.6-mg subcutaneous depot injection 
into the abdominal wall every 4 weeks), tamoxifen alone (20 or 
40 mg daily), both treatments, or no endocrine therapy (  Figure 1  ). 
Most women were younger than 50 years, with invasive, 
operable breast cancer confined to one breast without evidence 
of metastatic disease. Treatments were administered for 2 years. 
Women received primary therapy: surgery with or without 
radiotherapy and adjuvant systemic chemotherapy, where 
appropriate. Chemotherapy was perioperative cyclophosph-
amide, or six cycles of cyclophosphamide, methotrexate, and 
5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, and cyclo-
phosphamide (FEC). The proportions of patients who received 
surgery, radiotherapy, or chemotherapy were evenly distributed 
between the goserelin groups (  Supplementary Table 1  , available 
online), so these treatments would not be expected to affect the 
results.               
  All patients in the Stockholm and GIVIO trials were included 
in the 2 × 2 factorial random assignment. Patients in the CRUK 
and South East Sweden trials were initially randomly assigned into 
four arms, but with the publication of the data on tamoxifen in 
younger patients (  6  ), investigators were permitted to give tamox-
ifen electively, following random assignment to goserelin or no 
goserelin. This did not affect the results because the numbers of 
women treated and not treated with tamoxifen were balanced 
between the trial arms: Of those electively given tamoxifen, 432 
were randomly assigned to goserelin and 428 to no goserelin, and 
of those electively not given tamoxifen, 25 were randomly assigned 
to goserelin and 25 to no goserelin. 
  Four patients were subsequently found to have been ineligible 
at the time of random assignment (two had contralateral breast 
cancer, one had metastatic disease, and one had recurrent disease) 
and were excluded from this analysis. The numbers of women 
analyzed in the control, tamoxifen-only, goserelin-only, and both 
therapies arms were 476, 879, 469, and 882, respectively (2706 in 
total).   
    Outcomes 
  The following four outcome measures were examined    : (1) 
Event-free survival (EFS), the main trial endpoint and defined as 
a recurrence, new tumor, or death. (2) Overall survival (OS    , 
death from any cause). (3) Risk of recurrence [recurrence could 
be local or distant and among 10 women who died from breast 
cancer with no previously recorded recurrence, it was assumed 
that they had a distant recurrence, assumed to occur on the date 
of death; consistent with the assumptions of the EBCTCG over-
view (  3  )]. (4) Risk of dying from breast cancer. There were 520 
women known to have died from breast cancer. There were also 
110 whose cause of death was unknown, but these deaths also 
were assumed to be due to breast cancer because among those 
with a known cause of death, 90% were due to breast cancer. In 
addition, there were 13 women who died from other known 
    CONTEXT AND CAVEATS       
    Prior knowledge 
  Ovarian suppression by treatment with goserelin had been shown 
to reduce the risk of mortality in premenopausal breast cancer 
patients, but data on the long-term benefit of this treatment were 
lacking.   
    Study design 
  The analysis was based on a randomized trial with 2 × 2 factorial 
assignment of breast cancer patients younger than 50 years to no 
hormonal therapy or 2 years of treatment with tamoxifen alone, 
goserelin alone, or goserelin plus tamoxifen. Kaplan  –  Meier curves 
were constructed and hazard ratios and absolute risk reductions 
were calculated to compare treatment groups in terms of survival 
and recurrence outcomes.   
    Contribution 
  This study quantified the absolute risk reduction of mortality and 
recurrence conferred by goserelin treatment among women who 
did and did not take tamoxifen based on long-term follow-up 
(mean follow-up time = 11 years).   
    Implications 
  For every 100 women younger than 50 years and not treated with 
tamoxifen, 2 years of goserelin treatment would result in 8.5 fewer 
breast cancer deaths compared to those not given goserelin. The 
benefit of goserelin treatment in women treated with tamoxifen, if 
any, would be smaller (possibly 2.6 fewer deaths).   
    Limitations 
  Women in the trial were treated with tamoxifen for 2 years, which 
is currently not standard practice. The trial did not address the ques-
tion of the optimal frequency and duration of goserelin treatment. 
    From the Editors       
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causes but in whom breast cancer was present at death; these 
women were censored at the date of first recurrence because 
according to the EBCTCG overview (  3  ), cause of death may not 
be reliably recorded after a recurrence.   
    Statistical Analysis 
  The sample size target was set at 2700 women to detect an absolute 
difference in the 5-year EFS rate of 5% (70% vs 75% in the con-
trol and treated group, respectively), with 83% power and alpha set 
at .05. Simple randomization was used in each of the four trial 
groups to allocate patients to the trial arms with a block size of 
four. 
  Kaplan  –  Meier survival curves and hazard ratios (HRs) were 
used to compare treatment groups based on intention-to-treat 
analyses. We examined the interaction between goserelin and 
tamoxifen and whether the effect of goserelin differed between 
subgroups of patients for four prognostic factors: age (<40 or   ≥  40 
years), nodal status (positive or negative), ER status (positive, 
negative, or unknown), and previous adjuvant systemic chemo-
therapy (yes or no). Although age was not prespeciﬁ  ed in the origi-
nal trial protocol, the intention was to include it in the long-term 
follow-up analysis, particularly because it was examined in detail 
in the recent LHRH overview (  4  ). All analyses were stratiﬁ  ed by 
trial group. The assumption of proportional hazards was veriﬁ  ed 
using a plot of the Schoenfeld residuals (  7  ). Statistical analyses 
were performed using SAS 9.1 (  8  ). Because tamoxifen is the cur-
rent standard of treatment, most analyses were presented accord-
ing to whether women received tamoxifen or not, allowing an 
examination of the effect of goserelin in addition to tamoxifen. 
Relative or proportional risk reductions, based on hazard ratios, 
are indicated by percentages (%), whereas absolute risk differences 
at speciﬁ  ed time points are indicated by percentage points (ie, the 
number of events prevented among every 100 treated women). All 
statistical tests were two-sided, and   P   values less than .05 were 
considered statistically signiﬁ  cant.     
    Results 
  The median length of follow-up was 12 years, with 26 545 person-
years in total. The numbers of EFS events (recurrence, second 
primary tumor, or death), deaths, breast cancer recurrences, and 
breast cancer deaths were 1148, 690, 941, and 630, respectively 
(  Supplementary Table 2  , available online).         
  HRs associated with goserelin treatment according to trial 
group and overall for the four outcome measures are shown in 
(  Supplementary Table 3  , available online. Goserelin was associ-
ated with a risk reduction in all four endpoints: the risk of having 
an EFS event (HR    =    0.82, 95% conﬁ  dence interval [CI] 0.73 to 
0.92,   P      =    .001), overall mortality (HR    =    0.83, 95% CI 0.71 to 0.96, 
  P      =    .013), the risk of recurrence (HR    =    0.81, 95% CI 0.71 to 0.92, 
  P      =    .001), and breast cancer mortality (HR    =    0.82, 95% CI 
    0.70 to 0.96,   P      =    0.03). Although the point estimates of HR for 
EFS, OS, recurrence, and breast cancer mortality in the GIVIO 
trial appeared to differ from those of the other trials, the conﬁ  -
dence intervals contained the overall estimate for each outcome, 
suggesting that the differences may have been due to chance. 
There was a clear beneﬁ  t on survival and recurrence 10 or 15 years 
after randomization (  Figure 2  ).         
  The effect of goserelin depended on whether women received 
tamoxifen (  Table 1  ). The test for interaction was statistically sig-
niﬁ  cant for EFS and recurrence, and although the   P   values were 
greater than .05 for OS and breast cancer mortality, the HRs were 
in a direction       similar to the other endpoints, that is, women who 
did not receive tamoxifen experienced a greater beneﬁ  t from gos-
erelin than those who received tamoxifen. Thus, in women who did 
not receive tamoxifen, goserelin was associated with a 33% reduc-
tion in the risk of having an EFS event, a 29% reduction in risk of 
overall mortality, a 34% reduction in risk of recurrence, and a 29% 
reduction in risk of breast cancer mortality. In women who received 
tamoxifen, there was a much smaller beneﬁ  t due to goserelin: 8% 
reduction in risk of EFS events, 10% reduction in risk of overall 
mortality, 9% reduction in risk of recurrence, and 11% reduction 
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  Figure 2    .       Survival and disease outcomes according to goserelin treat-
ment.   A  ) The percentages (95% conﬁ   dence interval [CI]) of women 
treated with goserelin who experienced death, had recurrence, or had a 
new tumor at 5, 10, and 15 years were 25 (23 to 27), 38 (35 to 41), and 
47 (43 to 51), respectively; corresponding percentages in control women 
were 32 (29 to 35), 43 (40 to 46), and 52 (48 to 55).   B  ) The percentages 
(95% CI) of women treated with goserelin who died at 5, 10, and 15 
years were 12 (10 to 14), 21 (19 to 23), and 29 (26 to 32), respectively; the 
corresponding percentages in control women were 15 (13 to 17), 26 (23 
to 28), and 33 (30 to 36).   C  ) The percentages (95% CI) of women treated 
with goserelin who had a recurrence at 5, 10, and 15 years were 22 (20 
to 24), 31 (28 to 34), and 36 (33 to 39), respectively; the corresponding 
percentages in control women were 27 (24 to 29), 37 (34 to 40), and 42 
(39 to 45).   D  ) The percentages (95% CI) of women treated with goserelin 
who died from breast cancer at 5, 10, and 15 years were 11 (9 to 13), 20 
(18 to 22), and 26 (23 to 29), respectively; the corresponding percent-
ages in control women were 14 (12 to 16), 24 (22 to 26), and 30 (27 to 
33). Two-sided   P   values from log-rank tests are shown.       
in risk of breast cancer mortality.   Table 1   also shows that goserelin 
was as effective as tamoxifen; the hazard ratios for each treatment 
on its own were similar, when compared with the control group. 
  Kaplanmeier curves for the four treatment arms are shown in 
  Figure 3  . Taking either tamoxifen or goserelin had similar and 
large effects, but using both was associated with a possible small 
  Table 1    .       Examination of the interaction between goserelin and tamoxifen   
    Treatment
Hazard ratios  *   (95% confidence interval)     
  Any event    ‡    Death from any cause Breast cancer recurrence  ‡  Death from breast cancer  ‡     
    Tamoxifen    †          
         No 0.67 (0.56 to 0.81) 0.71 (0.56 to 0.91) 0.66 (0.53 to 0.81) 0.71 (0.55 to 0.92) 
         Yes 0.92 (0.79 to 1.06) 0.90 (0.74 to 1.09) 0.91 (0.77 to 1.07) 0.89 (0.73 to 1.09) 
  No endocrine therapy 1 (referent) 1 1 1 
  Tamoxifen alone 0.71 (0.60 to 0.84) 0.74 (0.60 to 0.91) 0.69 (0.57 to 0.83) 0.72 (0.58 to 0.90) 
  Goserelin alone 0.67 (0.56 to 0.81) 0.71 (0.56 to 0.91) 0.66 (0.53 to 0.81) 0.71 (0.55 to 0.92) 
  Both tamoxifen and goserelin 0.65 (0.55 to 0.78) 0.66 (0.54 to 0.83) 0.63 (0.52 to 0.76) 0.64 (0.51 to 0.81) 
  Tamoxifen alone 1 (referent) 1 1 1 
  Both tamoxifen and goserelin 0.92 (0.80 to 1.07) 0.90 (0.75 to 1.09) 0.91 (0.78 to 1.07) 0.89 (0.73 to 1.09) 
  Goserelin alone 11 1 1  
  Both tamoxifen and goserelin 0.97 (0.81 to 1.17) 0.93 (0.74 to 1.18) 0.95 (0.78 to 1.17) 0.90 (0.70 to 1.16)   
    *     The hazard ratios can be converted to percentage reduction or increase in risk by subtracting 1 and multiplying by 100.   
      †       The hazard ratios are for goserelin vs no goserelin. The   P   values for the test of interaction between goserelin and tamoxifen were .01 (any event), .13 (death from 
any cause), .016 (breast cancer recurrence), and .17 (death from breast cancer).   
      ‡       Recurrence, new tumor, or death.     jnci.oxfordjournals.org    JNCI | Articles 345
   
    Figure 3    .       Survival and disease outcomes according to each of the four treatment groups. Outcomes considered were death, recurrence, or new 
tumor (  A  ); death from any cause (  B  ); breast cancer recurrence (  C  ); and death due to breast cancer (  D  ). Two-sided   P   values from log-rank tests.         
  Table 2    .       Estimated absolute risk difference (percentage points) between goserelin and no goserelin for four outcomes   
    No. of years after randomization
Women who did not take tamoxifen (n = 945)    Women who took tamoxifen (n = 1761)     
  Absolute risk difference  *   
(95% confidence interval)
Number needed 
to treat    †   
Absolute risk difference 
(95% confidence interval)
Number needed 
to treat   
    Any event (recurrence, new tumor, 
  or  death)
      
          5    10.7 (    14.7 to     6.0) 9     1.9 (    5.1 to 1.4) 53 
         10     12.8 (    17.7 to     7.0) 8     2.5 (    6.8 to 1.8) 40 
         15     13.9 (    19.4 to     7.5) 7     2.8 (    7.7 to 2.0) 36 
  Death from any cause      
          5    4.6 (    7.1 to     1.4) 23     1.3 (    3.4 to 1.1) 77 
         10     7.6 (    11.9 to     2.3) 13     2.1 (    5.6 to 1.8) 48 
         15     9.2 (    14.4 to     2.7) 11     2.5 (    6.8 to 2.2) 40 
  Breast cancer recurrence      
           5    10.1 (    14.3 to     5.4) 10     1.9 (    5.0 to 1.4) 53 
         10     11.9 (    17.1 to     6.4) 8     2.5 (    6.6 to 1.9) 40 
         15     12.8 (    18.4 to     6.8) 8     2.8 (    7.5 to 2.1) 36 
  Death from breast cancer      
           5    4.4 (    7.0 to     1.2) 23     1.3 (    3.3 to 1.1) 77 
         10     7.3 (    11.7 to     1.9) 14     2.2 (    5.4 to 1.7) 45 
         15     8.5 (    13.7 to     2.2) 12     2.6 (    6.6 to 2.1) 38   
    *     If   P   is the event rate in the no goserelin arm (eg, EFS rate or risk of recurrence) at a specified time point, then the absolute difference at this time is 
  P        exp[hazard ratio × log  e    P   ]. The hazard ratios were taken from   Table 1   (tamoxifen = “No” or “Yes”).   
      †       Number needed to treat = 100% (absolute risk difference). The expected number of women who need to be treated with goserelin to avoid one event at the 
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additional beneﬁ  t that was not statistically signiﬁ  cant. We calcu-
lated absolute risk differences associated with goserelin treatment 
at 5, 10, and 15 years after random assignment among women who 
did or did not take tamoxifen (  Table 2  ). Among women who did 
not take tamoxifen, there was a clear and substantial beneﬁ  t associ-
ated with goserelin treatment for all four endpoints. For example, 
the estimated EFS absolute risk difference at 15 years indicates 
that for every 100 such women treated with goserelin, there could 
be 13.9 fewer with an event (recurrence, new tumor or death), 
compared with those not given goserelin (risk difference     13.9 
percentage points, 95% CI     19.4 to     7.5). This corresponds to a 
number needed to treat of 7. Among women who took tamoxifen, 
the beneﬁ  t was smaller and not statistically signiﬁ  cant: For every 
100 such women treated with goserelin, there could be 2.8 fewer 
with an event (95% CI     7.7 to 2.0). With regards to the effect on 
breast cancer mortality, 12 patients needed to be treated with gos-
erelin (and not tamoxifen) to avoid one woman dying       (risk differ-
ence     8.5 percentage points, 95% CI     13.7 to     2.2), compared 
with no goserelin, whereas 38 needed to be treated with both gos-
erelin and tamoxifen to avoid one death (risk difference     2.6 
percentage points, 95% CI     6.6 to 2.1). Risk differences and 
NNTs are likely   to be different in populations with much lower or 
higher baseline risks than in the ZIPP trial.       
  We also examined the absolute risk difference according to age 
(Table 3      ). Older women (  ≥  40 years) who did not take tamoxifen 
beneﬁ  ted the most: The absolute risk difference was 14.8 percent-
age points after 15 years. In younger women (<40 years), goserelin 
decreased the event rate by 4  –  5 percentage points at 15 years, but 
the conﬁ  dence intervals were wide, which may partly reﬂ  ect the 
smaller sample size in these subgroups. The least beneﬁ  t associated 
with goserelin treatment appeared to be among older women who 
took tamoxifen (the absolute risk was 1.7 percentage points lower). 
  Among younger women who had prior chemotherapy, the 
hazard ratio for goserelin treatment (compared with those not 
given goserelin) in relation to breast cancer mortality was 0.66 
(95% CI 0.44 to 0.98), and this reduction in risk did not seem to 
depend on whether they took tamoxifen or not (HRs 0.66 and 
0.63, respectively). The corresponding hazard ratio in younger 
women without prior chemotherapy was 0.86 (95% CI 0.55 to 
1.34). These observations could be partly explained by the fact 
that younger women derive greater beneﬁ  ts from adjuvant che-
motherapy. Among older women who had prior chemotherapy, 
the HR was 0.87 (95% CI 0.68 to 1.13), although the effect might 
be greater when they also took tamoxifen (HRs of 0.80 and 0.93, 
with and without tamoxifen, respectively). Among older women 
who did not have prior chemotherapy, the effect of goserelin 
depended on whether they took tamoxifen (HR for the effect of 
goserelin for older women who did or did not receive tamoxifen 
was 1.06 [95% CI = 0.75 to 1.52] and 0.60 [95% CI = 0.39 to 
0.93], respectively). 
  We investigated interactions between goserelin and four prog-
nostic factors (  Supplementary Table 4  , available online). The 
effect of goserelin was greatest among women who were node 
negative, those with ER-positive tumors, and those who had 
received no prior chemotherapy (although age and tamoxifen use 
inﬂ  uenced this). Similar to other studies, a beneﬁ  t of goserelin in 
women with ER-positive tumors was observed, whether they took 
tamoxifen or not. It is possible that the interaction between goser-
elin and nodal status might have been inﬂ  uenced by prior chemo-
therapy because women with node-positive tumors were more 
likely to receive chemotherapy. However, when patients were 
stratiﬁ  ed by nodal status and prior chemotherapy, there was still a 
tendency for the effect of goserelin to be greater among node-
negative women, although those who were node positive who had 
prior chemotherapy did not appear to beneﬁ   t from goserelin 
(  Supplementary Table 5  , available online).   
    Discussion 
  To our knowledge, the ZIPP trial is the largest that has investigated 
an LHRH agonist (2706 women) and the only factorial study that 
has evaluated goserelin and tamoxifen simultaneously with a control 
group of women who received no endocrine therapy. Recurrence 
and breast cancer mortality rates in both the tamoxifen and control 
arms were similar to those from the EBCTCG overview (  3  ). 
  The overview of LHRH agonists (  4  ), based on an average 
follow-up of 6.8 years, reported data on recurrence, death from any 
cause, and death after recurrence. The main conclusions were that 
LHRH agonists had an effect on reducing the risk of these events 
similar to that for chemotherapy (such as FEC or CMF), and could 
be used as an effective treatment in women with ER-positive tumors, 
either alone or in combination with chemotherapy or tamoxifen. 
Furthermore, there seemed to be a particular beneﬁ  t among younger 
women (<40 years) who had received chemotherapy. 
  Although our earlier data were included in the overview (  4  ), our 
results from the long-term follow-up (average follow-up is 12 
years) add further information on the effect of LHRH agonists and 
allow estimates of the absolute risk difference at 10 and 15 years 
after the start of treatment. In addition to information on recur-
rence and death from any cause, we analyzed the effect of goserelin 
  Table 3    .       Estimated absolute risk difference (percentage points) for any event (recurrence, new tumour or death) between women 
treated with goserelin and those not treated with goserelin, according to age and whether women took tamoxifen or not.   
Absolute risk difference (95% confidence interval)   *       
        No. of years since 
randomisation
Women who did not take tamoxifen    Women who took tamoxifen     
Age <40 years (n = 191) Age   ≥   40 years (n = 754) Age < 40 years (n = 415) Age   ≥   40 years (n = 1346    )
    5    3.6 (    15.0 to +10.1)     11.2 (    15.8 to     6.2)     4.3 (    11.0 to +3.8)     1.1 (    4.3 to +2.9) 
  10     4.0 (    17.3 to +10.9)     13.4 (    19.2 to     7.3)     5.1 (    13.2 to +4.3)     1.5 (    6.1 to +3.9) 
  15     4.2 (    18.6 to +11.0)     14.8 (    21.5 to     7.9)     5.5 (    14.7 to +4.5)     1.7 (    7.0 to +4.4) 
  Hazard ratio (95% CI) 0.89 (0.58  –  1.35) 0.65 (0.52  –  0.80) 0.86 (0.66  –  1.13) 0.95 (0.80  –  1.14).   
    *     If   P      =    the event rate in the ‘no goserelin  ’   arm at a specified time point, then the absolute risk difference at this time is   P   minus exp[hazard ratio x log  e    P  ].     jnci.oxfordjournals.org    JNCI | Articles 347
on the chance of dying from breast cancer and the chance of hav-
ing any event (recurrence, new tumor, or death). Our analysis also 
quantiﬁ   ed the long-term effect of goserelin separately among 
women who did or did not have tamoxifen. Because tamoxifen is 
now offered routinely to many women, it is important to know 
what the additional beneﬁ  t of goserelin is 10 and 15 years after the 
initiation of treatment. 
  Among women who did not receive tamoxifen, goserelin was 
associated with large reductions in the event rate, the chance of 
dying from any cause or from breast cancer, and the risk of having 
a recurrence; the effect remained substantial 15 years later. Although 
the effect of goserelin was smaller (and not statistically signiﬁ  cant) 
among women who took tamoxifen, a difference in risk of 2  –  3 per-
centage points in absolute risk at 15 years might be important, given 
the high incidence of early breast cancer. This would correspond 
to treating 33  –  50 women with tamoxifen and goserelin to avoid 
one woman having a recurrence, new tumor, or death. Indeed, the 
  number needed to treat at 15 years was 18 in women younger than 
40 years who also took tamoxifen (Table 3      ). 
  The effect of goserelin was greatest in women who were 
node negative and in those with ER-positive tumors. Our results 
were also consistent with the observation that the effect of 
goserelin may be greater in younger women who had prior che-
motherapy (  4  ). 
  A limitation of our trial is that it was based on 2 years of tamox-
ifen treatment, like many other studies at the time, though it is now 
standard practice to treat women for 5 years. Data from the INT 
0101 trial, in which all women received chemotherapy, showed 
that the combination of 5 years of goserelin and tamoxifen was 
associated with a 9-year disease-free rate that was 9 and 7 percent-
age points higher among younger (<40 years) and older (  ≥  40) 
women, respectively, compared with those treated with goserelin 
alone (  9  ). Furthermore, there is evidence that a large proportion of 
women discontinue tamoxifen before 5 years. In a cohort of 2816 
women in Ireland, 20% had stopped by 3.5 years with no further 
hormonal therapy (  10  ). Therefore, the effect of 2 years of goserelin 
or tamoxifen therapy might still be relevant in these women. 
  Data on the tolerability of goserelin were presented in our ﬁ  rst 
report (  5  ). The most common side effect was hot ﬂ  ashes: This was 
experienced by none of the control patients, 26% of patients 
treated with goserelin, 17% of those treated with tamoxifen, and 
44% of those who received goserelin plus tamoxifen. In a trial of 
874 women with lymph node  –  negative breast cancer randomly 
assigned to receive six courses of CMF chemotherapy, goserelin 
for 2 years, or CMF followed by 18 months of goserelin, a greater 
proportion of women who received goserelin alone had hot ﬂ  ashes 
compared with those treated with CMF alone (  11  ). However, in 
the goserelin group, the incidence 3 years later was similar to that 
in baseline, but not in those who received CMF. This effect is 
expected, given that amenorrhea can be induced by either chemo-
therapy or goserelin, but is reversible after stopping goserelin but 
permanent after chemotherapy. Goserelin was also associated with 
an improvement in quality-of-life measures such as mood, coping 
effort, tiredness, nausea       and/or vomiting, and overall subjective 
assessment of health, compared with CMF alone (  11  ). 
  Treatment-induced bone loss is a side effect of ovarian ablation 
or aromatase inhibitor therapy, which increases the risk of frac-
tures or spinal cord compression (  12  ). In a subgroup of patients 
randomly assigned to receive goserelin (n = 53) for 2 years or CMF 
chemotherapy for 6 months (n = 43), loss of bone mineral density 
(BMD) was greater in the goserelin group (  13  ). Although there was 
partial recovery 1 year after stopping goserelin, the bone loss in the 
CMF group persisted. Although the combination of goserelin and 
tamoxifen may have a small additional beneﬁ   t compared with 
either alone, there may be a further case for recommending both 
therapies because of the possible mitigating effect of tamoxifen on 
BMD. Markers of bone health were not measured in all women in 
the ZIPP trial, but the effects of 2 years of treatment with goserelin 
and tamoxifen on BMD were examined in a subgroup (n = 89) of 
patients in the Stockholm group (  14  ). The reduction in BMD was 
5% in the patients treated with goserelin (with partial recovery 1 
year after stopping therapy) and 1.4% in the patients treated with 
tamoxifen and goserelin. 
  There is accumulating evidence that zoledronic acid combined 
with endocrine therapy can also help prevent BMD loss. In a trial of 
401 patients treated with goserelin, women were randomly assigned 
to receive 3 years of either tamoxifen or anastrazole, each with or 
without zoledronic acid (  15  ). There were reductions in lumbar spine 
and trochanter BMD when tamoxifen or anastrazole was used alone, 
but no material reduction when zoledronic acid was added. A com-
bined interim analysis of two recent randomized trials, Z-FAST and 
ZO-FAST (total from both trials, n = 1667), in which all women 
received adjuvant letrozole, compared giving zoledronic acid either at 
the time of random assignment or only if their bone density fell below 
a prespeciﬁ  ed cutoff or they suffered a nontraumatic fracture (  16  ). 
After 1 year, the score for lumbar spine BMD was 5.2% higher in the 
patients given zoledronic acid at the time of random assignment, and 
the total hip score was 3.5% higher. There was also evidence that the 
risk of recurrence was lower in these patients. The effect of zole-
dronic acid on survival and recurrence has been conﬁ  rmed in a large 
trial of 1801 premenopausal women randomly assigned to receive 
endocrine therapy (tamoxifen or anastrozole), with or without zole-
dronic acid, with all women receiving goserelin (  17  ). The risk of 
death or recurrence was reduced by 35% (95% CI     =     8% to 54%) 
among women who were given zoledronic acid. Given its beneﬁ  ts in 
terms of both bone health and clinical outcome, zoledronic acid could 
be considered as an additional treatment to goserelin. 
  The optimal frequency and duration of treatment with LHRH 
agonists are unknown. In the ZIPP trial, goserelin was given 
monthly for 2 years. Evidence from a randomized trial of 599 
women with node-positive breast cancer indicated that a less fre-
quent schedule (3-monthly depot of the LHRH agonist leuprore-
lin acetate, 11.25 mg) may be as beneﬁ  cial as CMF chemotherapy 
in terms of the effect—5-year recurrence-free survival (HR 0.97) 
and after 2 years OS was better in patients given leuprorelin ace-
tate (HR 0.64, 95% CI 0.46 to 0.90) (  18  ). Nevertheless, no trial has 
speciﬁ  cally addressed the question of the optimal frequency and 
duration of goserelin treatment. 
  In summary, long-term follow-up of our large trial showed that 
goserelin had a demonstrable effect on survival and recurrence 
15 years after starting treatment and is as effective as tamoxifen 
when each are given for 2 years. The beneﬁ  t was greatest among 
women who did not receive tamoxifen (among every 100 women 
treated with goserelin, there could be 8.5 fewer breast cancer 348   Articles | JNCI  Vol. 101, Issue 5  |  March 4, 2009
deaths), and there was a possible gain in those who did receive 
tamoxifen (among every 100 women treated with goserelin, there 
could be 2.6 fewer breast cancer deaths). It may be that women 
who are unlikely to complete 5 years of tamoxifen tablets may 
prefer 2 years of goserelin injections. It may also be reasonable to 
recommend both therapies to minimize the reduction in BMD 
associated with endocrine treatment.         
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